Federal award (DEFINITIVE CONTRACT, fiscal year 2023)
Recipient: VENATORX PHARMACEUTICALS INC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2016-09-19 to 2026-03-31
Current total value of award: $48498140.75
Description: THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEVELOPMENT (CLIN 001); A BETA-LACTAM CLINICAL STUDY (CLIN 002); A NON-GLP